Showing 4071-4080 of 5646 results for "".
- EssilorLuxottica Supports New WSPOS Independent Medical Education Program on Myopia Managementhttps://modernod.com/news/essilorluxottica-supports-new-wspos-independent-medical-education-program-on-myopia-management/2481243/EssilorLuxottica announced it is supporting the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) independent medical education program on myopia management, as a gold level supporter, which will be launched on November 19 and 20, at 2-4pm GMT. The key goals of this progr
- Luminopia Announces Oversubscribed Seed Extension Financing Round to Fund Amblyopia Treatmenthttps://modernod.com/news/luminopia-announces-oversubscribed-seed-extension-financing-round-to-fund-amblyopia-treatment/2481237/Luminopia, a prescription digital therapeutics company developing a new class of treatments for neuro-visual disorders, announced an oversubscribed $5.7M seed extension financing round. The company will be using the funding for a staged rollout of its lead product for amblyopia to pediatric
- Harrow Launches Atropine.comhttps://modernod.com/news/harrow-launches-atropinecom/2481236/Harrow announced the launch of atropine.com, an ordering and marketing portal designed specifically for prescribers interested in compounded atropine formulations. All atropine.com, prescriptions will be dispensed through Harrow’s wholly owned
- Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-announces-positive-results-in-safety-durability-and-biologic-effect-in-oasis-phase-12a-clinical-trial-of-suprachoroidal-cls-ax-in-wet-amd-patients/2481234/Clearside Biomedical announced positive results from its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) patients. Trial results include f
- Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-plans-to-submit-24-month-phase-3-data-to-the-fda-for-pegcetacoplan-nda-for-geographic-atrophy-ga/2481233/Apellis Pharmaceuticals provided an update on its new drug application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company plans to submit the 24-month efficacy data from the phase 3 DERB
- Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officerhttps://modernod.com/news/atsena-therapeutics-expands-leadership-team-with-appointment-of-lis-leiderman-md-mba-as-chief-financial-officer-and-chief-business-officer/2481229/Atsena Therapeutics announced the appointment of Elisabeth (Lis) Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer. Dr. Leiderman has more than 15 years of finance, business development and strategy experience in the life sciences industry, most recently with gene the
- Iveric Bio Submits First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophyhttps://modernod.com/news/iveric-bio-submits-first-part-of-nda-for-rolling-review-of-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/2481227/Iveric bio announced that it has submitted to the FDA the first part of its new drug application (NDA) for rolling review of avacincaptad pegol (ACP, also known as Zimura) a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to age-related m
- Kinarus Therapeutics Provides Strategic Updatehttps://modernod.com/news/kinarus-therapeutics-provides-strategic-update/2481226/Kinarus Therapeutics reiterated its plans to focus on clinical trials in wet age-related macular degeneration (AMD) and idiopathic pulmonary fibrosis, and to refocus its capital resources and financing efforts to drive these programs. Following the discontinuation of the phase 2 KINETIC
- The Vision Council Releases Focused inSights 2022: Digital Habitshttps://modernod.com/news/the-vision-council-releases-focused-insights-2022-digital-habits/2481225/The Vision Council has released "Focused inSights 2022: Digital Habits." The survey asked respondents how they use digital devices, if they were affected by digital eyestrain, their online purchasing habits, their social media use, and their experience with telehealth for eye care. The
- Market Scope: Safer and More Effective Glaucoma Surgical Options Expected to Double Global Revenue by 2027https://modernod.com/news/market-scope-safer-and-more-effective-glaucoma-surgical-options-expected-to-double-global-revenue-by-2027/2481223/Nearly 48 million individuals are diagnosed with glaucoma globally, but just over a million, or 2.2 percent, will have surgery in 2022. However, safer and more effective surgical devices over the next 5 years will increase the percentage of glaucoma patients treated surgically to a projected 3.5